Vaknin Rachel 4

What Happened
Rachel Vaknin, Chief Financial Officer of Microbot Medical, received a grant of derivative awards covering 105,000 shares on February 18, 2026. The Form 4 reports the acquisition as an award/ grant (code A) with a reported price of $0.00 at grant — this is a stock award/option-style grant rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-18; Form 4 filed: 2026-02-20 (appears timely; Form 4s are generally due within two business days).
• Security: derivative award covering 105,000 shares (reported price $0.00).
• Shares owned after transaction: not specified in the filing.
• Plan: Issuer’s 2020 Omnibus Performance Award Plan, as amended.
• Footnote: Vesting schedule — 25% vests on August 18, 2026; the remaining 75% vests quarterly over the subsequent 30 months, subject to acceleration or forfeiture under the Plan.

Context
This was a grant of equity-based awards (derivative instruments) rather than a purchase of shares. Such grants are common for executive compensation and do not by themselves indicate buying or selling sentiment; vesting conditions and future exercise/sale behavior determine potential insider exposure. The award’s vesting schedule includes time-based installments and is subject to plan terms.